The US Food and Drug Administration (FDA) has extended its time-frame for review of the promising new biologic Stelara (ustekinumab) for moderate to severe psoriasis by 90 days. That would mean we can expect a decision about Stelara by the fall of 2009. Stelara has already been approved for use in Canada.
Category: Biologics, Psoriasis Research
Tags: FDA, Stelara, ustekinumab
